Needham & Company LLC Cuts Artivion (NYSE:AORT) Price Target to $32.00

Artivion (NYSE:AORT) had its price target decreased by Needham & Company LLC from $34.00 to $32.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s price target would indicate a potential upside of 14.70% from the stock’s previous close.

Several other equities analysts have also recently issued reports on AORT. JMP Securities reiterated a “market outperform” rating and issued a $33.00 price target on shares of Artivion in a report on Tuesday, December 10th. Oppenheimer raised their target price on shares of Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research report on Friday, November 8th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $31.40.

Artivion Stock Performance

NYSE:AORT opened at $27.90 on Tuesday. The firm has a market capitalization of $1.17 billion, a PE ratio of -1,394.90 and a beta of 1.75. The firm has a 50-day moving average price of $29.75 and a 200 day moving average price of $27.83. Artivion has a 12-month low of $18.38 and a 12-month high of $32.33. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71.

Insider Transactions at Artivion

In other Artivion news, SVP Jean F. Holloway sold 8,070 shares of Artivion stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $30.12, for a total transaction of $243,068.40. Following the completion of the transaction, the senior vice president now owns 153,862 shares in the company, valued at approximately $4,634,323.44. The trade was a 4.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Andrew M. Green sold 7,618 shares of the company’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $30.00, for a total transaction of $228,540.00. Following the completion of the sale, the vice president now directly owns 33,503 shares of the company’s stock, valued at $1,005,090. The trade was a 18.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 20,017 shares of company stock worth $600,007. Company insiders own 8.10% of the company’s stock.

Institutional Investors Weigh In On Artivion

A number of hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP boosted its stake in Artivion by 2.9% in the 3rd quarter. Wellington Management Group LLP now owns 1,656,264 shares of the company’s stock worth $44,090,000 after purchasing an additional 46,267 shares during the period. Wasatch Advisors LP lifted its holdings in shares of Artivion by 27.7% in the fourth quarter. Wasatch Advisors LP now owns 1,041,992 shares of the company’s stock worth $29,791,000 after buying an additional 226,160 shares in the last quarter. Next Century Growth Investors LLC lifted its holdings in shares of Artivion by 29.7% in the fourth quarter. Next Century Growth Investors LLC now owns 492,653 shares of the company’s stock worth $14,085,000 after buying an additional 112,918 shares in the last quarter. Northern Trust Corp boosted its position in shares of Artivion by 10.0% in the fourth quarter. Northern Trust Corp now owns 463,250 shares of the company’s stock valued at $13,244,000 after acquiring an additional 42,170 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in Artivion by 2.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 358,192 shares of the company’s stock valued at $10,241,000 after acquiring an additional 8,343 shares in the last quarter. Institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.